Biomednewsbreaks - Lantern Pharma (NASDAQ: LTRN) To Present AI-Driven Neuro-Oncology Strategy At Glioblastoma Summit

(MENAFN- Investor Brand Network) Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence to accelerate oncology drug discovery and development, announced that Chief Executive Officer and President Panna Sharma will present at the 7th Glioblastoma Drug Development Summit, taking place Feb. 17–19, 2026, in Boston. During a Day Two presentation on Feb. 19, Mr. Sharma will highlight how the Company's RADR® AI and machine learning platform supported the development of STAR-001, a brain-penetrant therapeutic candidate, including insights into mechanism of action, biomarker identification, indication selection, and novel combination strategies for aggressive CNS cancers such as glioblastoma and ATRT.

To view the full press release, visit

About Lantern Pharma

Lantern Pharma (NASDAQ: LTRN) is a clinical-stage biotechnology company using artificial intelligence, machine learning, and genomic data to streamline oncology drug development and bring precision therapies to patients who need them. The company's proprietary RADR(R) AI platform integrates hundreds of billions of data points to identify biomarkers, predict drug response, and design smarter clinical trials. Lantern's clinical-stage pipeline includes LP-184, LP-284, and LP-300, each targeting genomically defined patient populations.

NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company's newsroom at

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio IBN: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: /Disclaimer

BioMedWire
Austin, Texas

512.354.7000 Office
[email protected]

BioMedWire is powered by IBN

MENAFN10022026000224011066ID1110722666